Septerna
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 68
- Market Cap
- -
- Introduction
Septerna, Inc. is a clinical-stage biotechnology company, which engages in pioneering a new era of G protein-coupled receptor oral small molecule drug discovery powered by proprietary Native Complex PlatformTM. Its pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. The company was founded by Robert Joseph Lefkowitz, Arthur Christopoulos, Patrick Sexton, and Jeffrey T. Finer in December 2019 and is headquartered in South San Francisco, CA.
Clinical Trials
5
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Oral Care Study on Burn Patients
- Conditions
- Burn
- First Posted Date
- 2011-02-24
- Last Posted Date
- 2016-10-13
- Lead Sponsor
- Saint Elizabeth Regional Medical Center
- Registration Number
- NCT01302457
- Locations
- 🇺🇸
Saint Elizabeth Regional Medical Center, Lincoln, Nebraska, United States
Effect of Cranberry Extract on Infections in Burn Patients
- Conditions
- Burn
- Interventions
- Dietary Supplement: Cranberry ExtractDrug: Inert Placebo Capsule
- First Posted Date
- 2010-10-20
- Last Posted Date
- 2016-10-13
- Lead Sponsor
- Saint Elizabeth Regional Medical Center
- Registration Number
- NCT01225107
- Locations
- 🇺🇸
Saint Elizabeth Regional Medical Center, Lincoln, Nebraska, United States
Efficiency and Efficacy of the Distress Thermometer in the Burn and Wound Population (Research Mentoring High Student Project)
- Conditions
- Burns
- First Posted Date
- 2010-07-26
- Last Posted Date
- 2010-07-26
- Lead Sponsor
- Saint Elizabeth Regional Medical Center
- Registration Number
- NCT01169285
A Prospective Study of Body Image, Social Avoidance and Distress and Psychological Functioning in Burn Patients
- Conditions
- DepressionAnxietyBody Image
- First Posted Date
- 2010-06-03
- Last Posted Date
- 2016-10-13
- Lead Sponsor
- Saint Elizabeth Regional Medical Center
- Registration Number
- NCT01136070
- Locations
- 🇺🇸
Saint Elizabeth Regional Medical Center, Lincoln, Nebraska, United States
Cesarean Postoperative Pain Satisfaction
- Conditions
- Cesarean
- First Posted Date
- 2009-06-17
- Last Posted Date
- 2011-07-20
- Lead Sponsor
- Saint Elizabeth Regional Medical Center
- Target Recruit Count
- 120
- Registration Number
- NCT00922142
- Locations
- 🇺🇸
Saint Elizabeth Regional Medical Center, Lincoln, Nebraska, United States
News
Novo Nordisk and Septerna Partner on $2.2 Billion Deal to Develop Oral Obesity Treatments
Novo Nordisk and Septerna have formed a $2.2 billion collaboration to develop oral small molecule therapies targeting GLP-1, GIP, and glucagon receptors for obesity and cardiometabolic diseases.
Novo Nordisk Invests $2 Billion in Chinese "Triple G" Weight Loss Treatment
Novo Nordisk has committed $2 billion to develop a novel "triple G" weight loss injection in China, expanding its portfolio beyond its successful GLP-1 medications Ozempic and Wegovy.
Septerna Halts Phase 1 Trial of SEP-786 for Hypoparathyroidism Due to Safety Concerns
Septerna discontinues Phase 1 trial of SEP-786, an oral PTH1R agonist for hypoparathyroidism, following two cases of severe elevated unconjugated bilirubin in multiple-ascending dose study.
Septerna Raises $288M in Upsized IPO to Advance Novel GPCR-Targeting Drug Pipeline
• Septerna successfully completed an upsized IPO raising $288 million, selling 16 million shares at $18 each, demonstrating strong investor confidence in clinical-stage biotech companies. • The company's lead drug candidate SEP-786, targeting hypoparathyroidism, recently entered Phase 1 clinical trials with data expected by mid-2025. • Septerna plans to allocate $117 million of the proceeds to advance SEP-786 and $37 million for developing SEP-631 for chronic spontaneous urticaria and mast cell conditions.
Septerna Initiates Phase 1 Trial of Oral PTH1R Agonist SEP-786 for Hypoparathyroidism
Septerna has commenced a Phase 1 clinical trial for SEP-786, a novel oral small molecule agonist targeting the parathyroid hormone 1 receptor (PTH1R).